A Phase 1 Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy.

Trial Profile

A Phase 1 Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs SB 01 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors SynCore Biotechnology
  • Most Recent Events

    • 02 Jun 2017 Results (n=33), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 09 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top